Last $0.49 USD
Change Today 0.00 / 0.00%
Volume 0.0
LIXT On Other Exchanges
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

lixte biotechnology holdings (LIXT) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/13/13 - $0.70
52 Week Low
01/29/14 - $0.07
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

lixte biotechnology holdings (LIXT) Related Businessweek News

No Related Businessweek News Found

lixte biotechnology holdings (LIXT) Details

Lixte Biotechnology Holdings, Inc., a development stage cancer drug discovery company, develops treatments for human cancers. It develops anti-cancer drugs for life-threatening diseases using biomarker technology. The company focuses on the development of protein phosphatase inhibitors, such as the LB-100 series of compounds; and histone deacetylase inhibitors, including the LB-200 series of compounds for the treatment of cancer, as well as in the prevention and treatment of neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in East Setauket, New York.

lixte biotechnology holdings (LIXT) Top Compensated Officers

Founder, Chairman of the Board, Chief Executi...
Total Annual Compensation: $60.0K
Compensation as of Fiscal Year 2012.

lixte biotechnology holdings (LIXT) Key Developments

Lixte Biotechnology Holdings, Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 03:45 PM

Lixte Biotechnology Holdings, Inc. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 03:45 PM. Venue: New York Palace Hotel – 455 Madison Avenue, New York, NY 10022, United States.

Lixte Biotechnology Holdings, Inc. Auditor Raises 'Going Concern' Doubt

Lixte Biotechnology Holdings, Inc. filed its 10-K on Mar 21, 2014 for the period ending Dec 31, 2013. In this report its auditor, Weinberg & Company, P.A., gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Daniel Von Hoff Joins Lixte Biotechnology's Scientific Advisory Board

Lixte Biotechnology Holdings, Inc. announced the appointment of Daniel D. Von Hoff, MD, FACP, to the company's Scientific Advisory Board. Dr. Von Hoff is currently Physician in Chief, Distinguished Professor and Director of Clinical Translational Research Division at TGen.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LIXT:US $0.49 USD 0.00

LIXT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LIXT.
View Industry Companies

Industry Analysis


Industry Average

Valuation LIXT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 22.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIXTE BIOTECHNOLOGY HOLDINGS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at